PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 270 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $249,613 | -30.7% | 8,136 | -9.4% | 0.00% | -25.0% |
Q2 2023 | $359,949 | -6.6% | 8,983 | -4.9% | 0.00% | -20.0% |
Q1 2023 | $385,573 | +3.9% | 9,448 | -1.7% | 0.01% | 0.0% |
Q4 2022 | $371,274 | -23.4% | 9,616 | +5.5% | 0.01% | -28.6% |
Q3 2022 | $485,000 | +9.0% | 9,117 | +19.5% | 0.01% | +16.7% |
Q2 2022 | $445,000 | -9.2% | 7,631 | +18.9% | 0.01% | +20.0% |
Q1 2022 | $490,000 | +33.9% | 6,419 | +5.5% | 0.01% | +25.0% |
Q4 2021 | $366,000 | +10.2% | 6,086 | +2.7% | 0.00% | +33.3% |
Q3 2021 | $332,000 | -12.6% | 5,928 | -5.3% | 0.00% | -25.0% |
Q2 2021 | $380,000 | -7.5% | 6,259 | +6.8% | 0.00% | 0.0% |
Q1 2021 | $411,000 | +26.9% | 5,858 | +8.2% | 0.00% | 0.0% |
Q4 2020 | $324,000 | +4.2% | 5,413 | +4.8% | 0.00% | 0.0% |
Q3 2020 | $311,000 | +188.0% | 5,165 | +151.6% | 0.00% | +100.0% |
Q2 2020 | $108,000 | +74.2% | 2,053 | +11.3% | 0.00% | +100.0% |
Q1 2020 | $62,000 | -10.1% | 1,844 | +21.2% | 0.00% | 0.0% |
Q4 2019 | $69,000 | +16.9% | 1,521 | -1.0% | 0.00% | 0.0% |
Q3 2019 | $59,000 | -98.2% | 1,537 | -98.3% | 0.00% | -98.0% |
Q1 2019 | $3,354,000 | -42.6% | 88,124 | -35.1% | 0.05% | -49.0% |
Q4 2018 | $5,841,000 | -19.2% | 135,779 | -7.7% | 0.10% | -5.9% |
Q3 2018 | $7,228,000 | +45.0% | 147,068 | -5.5% | 0.10% | +37.8% |
Q2 2018 | $4,986,000 | +18.6% | 155,554 | +15.3% | 0.07% | +13.8% |
Q1 2018 | $4,204,000 | -39.8% | 134,948 | -11.7% | 0.06% | -38.7% |
Q4 2017 | $6,978,000 | +23.0% | 152,857 | +1.2% | 0.11% | +14.0% |
Q3 2017 | $5,673,000 | +96.0% | 151,078 | +149.0% | 0.09% | +86.0% |
Q2 2017 | $2,894,000 | +1.6% | 60,662 | -2.9% | 0.05% | -2.0% |
Q1 2017 | $2,848,000 | +176.0% | 62,464 | +95.6% | 0.05% | +168.4% |
Q4 2016 | $1,032,000 | -6.0% | 31,938 | -0.5% | 0.02% | -13.6% |
Q3 2016 | $1,098,000 | +1.4% | 32,098 | 0.0% | 0.02% | -4.3% |
Q2 2016 | $1,083,000 | -15.2% | 32,098 | +33.2% | 0.02% | -17.9% |
Q1 2016 | $1,277,000 | -31.3% | 24,098 | -0.4% | 0.03% | -33.3% |
Q4 2015 | $1,858,000 | +87.9% | 24,198 | +0.6% | 0.04% | +82.6% |
Q3 2015 | $989,000 | -41.9% | 24,056 | 0.0% | 0.02% | -37.8% |
Q2 2015 | $1,701,000 | -20.4% | 24,056 | 0.0% | 0.04% | -19.6% |
Q1 2015 | $2,137,000 | -2.6% | 24,056 | -2.8% | 0.05% | -6.1% |
Q4 2014 | $2,194,000 | – | 24,746 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |